secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008293
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics reports 2022 net loss $44.4M; cash $60.8M funds to mid-2024
-------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments $60.8M; expected to fund operations until mid-2024.
- Net loss Q4 2022 $5.1M, full year $44.4M; non-GAAP net loss $6.4M and $22.9M respectively.
- REASSURE trial enrollment ongoing, expected completion H1 2024; interim analysis at 50% enrollment H2 2023.
- Two new US patents issued for oral sulopenem (composition and method of use), expiring no earlier than 2039.
- Shareholder class action lawsuit dismissed with prejudice on January 25, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023008293/0000950170-23-008293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023008293/itrm-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer